From the Study of Tumor Cell Immunogenicity to the Generation of Antitumor Cytotoxic Cells in Non-Hodgkin's Lymphomas

References

• Heslop H. E., Rooney C. M. Adoptive cellular immunotherapy for EBV lymphoproliferative diseases. Immunol Rev 1997; 157: 217–222
   PubMed Web of Science ®Google Scholar
• Hsu F. J., Benike C., Fagnoni F., Liles T. M., Czerwinski D., Taidi B., Engleman E. G., Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 1996; 2: 52–58
   PubMed Web of Science ®Google Scholar
• Nestle F. O., Alijagic S., Gillet M., Sun Y., Grabbe S., Dummer R., Burg G., Schadendorf D. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Medicine 1998; 4: 328–332
   PubMed Web of Science ®Google Scholar
• Höltl L., Rieser C., Papesh C., Ramoner R., Bartsch G., Thurnher M. CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal cell cancer. Lancet 1998; 352: 1358–1358
   PubMed Web of Science ®Google Scholar
• Krieger J. I., Grammer S. F., Grey H. M., Chesnut R. W. Antigen presentation by splenic B cells: resting B cells are ineffective, whereas activated B cells are effective accessory cells for T cell responses. J. Immunol 1985; 135: 2937–2945
   PubMed Web of Science ®Google Scholar
• Eriksson Villacres M. Antigen presentation by naive macrophages, dendritic cells and B cells to primed T lymphocytes and their cytokine production following exposure to immunosfimulating complexes. Clin Exp Immunol 1995; 102: 46–52
   PubMed Web of Science ®Google Scholar
• Liu Y. J., Barthelemy C., De Bouteilleer O., Arpin C., Durand I., Banchereau J. Memory B cells from human tonsils colonize mucosal epithelium and directly present antigen to T cells by rapid up-regulation of B7–1 and B7–2. Immunity 1995; 2: 239–248
   PubMed Web of Science ®Google Scholar
• Milich D. R., Chen M., Schodel K, Peterson D. L., Jones J. E., Hughes J. L. Role of B cells in antigen presentation of the hepatitis B core. Proc Natl Acad Sci U S A 1997; 94: 14648–53
   PubMed Web of Science ®Google Scholar
• Constant S. B lymphocytes as antigen-presenting cells for CD4+ T cell priming in vivo. J. Immunol 1999; 162: 5695–5703
   PubMed Web of Science ®Google Scholar
• Harris N. L., Jaffe E. S., Stein H., Banks P. M., Chan J. K.C., Cleary M. L., Delsol G., Dewolfpeeters C., Falini B., Gatter K. C., Grogan T. M., Isaacson P. G., Knowles D. M., Mason D. Y., Mullerhermelink H. K., Pileri S. A., Piris M. A., Ralfkiaer E., Wamke R. A. A revised european-american classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Makgoba M. W., Sanders M. E., Shaw S. The CD2-LFA-3 and LFA-1-ICAM pathways: relevance to T-cell recognition. Immunol Today 1989; 10: 417–422
   PubMedGoogle Scholar
• Springer T. A. Adhesion receptors of the immune system. Nature 1990; 346: 425–434
   PubMed Web of Science ®Google Scholar
• Clark E. A., Ledbetter J. A. How B cells and T cells talk to each other. Nature 1994; 367: 425–428
   PubMed Web of Science ®Google Scholar
• Tohma S., Hirohata S., Lipsky P. E. The role of CDlla/CD18-CD54 interactions in human T cell dependent B cell activation. J Immunol 1991; 146: 492–499
   PubMed Web of Science ®Google Scholar
• Le Guiner S., Le Drean E., Labarriere N., Fonteneau J.-F., Viret C., Diez E., Jotereau F. LFA-3 co-stimulates cytokine secretion by cytotoxic T lymphocytes by providing a TCR-independent activation signal. Eur. J. Immunol 1998; 28: 1322–1331
   PubMed Web of Science ®Google Scholar
• Koopman G., Keehnen R. M.J., Lindhout E., Newman W., Shimizu Y., Van Seventer G. A., De Groot C., Pals S. T. Adhesion through LFA-1 (CDlla/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B ceils. J. Immunol 1994; 152: 3760–3767
   PubMed Web of Science ®Google Scholar
• Shaw S., Luce G. E., Quinones R., Gress R. E., Springer T. A., Sanders M. E. Two antigen-independant pathways used human cytotoxic T-cell clones. Nature 1986; 323: 262–264
   PubMed Web of Science ®Google Scholar
• Jansen J. H., Van der Harst D., Wientjens G.-J. H.M., Kooy-Winkelaar Y. M.C., Brand A., Willemze R., Kluin-Nelemans H. C. Induction of CD1la/leucocyte function antigen-1 and CD54/intercellular adhesion molecule-1 on hairy cell leukemia cells is accompanied by enhanced susceptibility to T-cell but not lymphokine-activated killer-cell cytotoxicity. Blood 1992; 80: 478–483
   PubMed Web of Science ®Google Scholar
• Altomonte M., Gloghini A., Bertola G., Gasparollo A., Carbone A., Ferrone S., Maio M. Differential expression of cell adhesion molecules CD54/CDlla and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res 1993; 53: 3343–8
   PubMed Web of Science ®Google Scholar
• Foreman N. K., Rill D. R., Coustan S. E., Douglass E. C., Brenner M. K. Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication. Br J Cancer 1993; 67: 933–8
   Google Scholar
• Jacob M.-C., Agrawal S., Chaperot L., Giroux C., Gressin R., Le Marc'Hadour E, Fabre M., Sotto J.-J., Bensa J.-C., Plumas J. Quantification of cellular adhesion molecules (CAMs) on malignant B cells from non-Hodgkin's lymphoma. Leukemia 1999; 13: 1428–1433
   PubMed Web of Science ®Google Scholar
• Chaperot L., Jacob M.-C., Le Vacon R, Giroux C., Molens J.-P., Sotto J.-J., Bensa J.-C., Plumas J. Relationships between susceptibility to LAK cell-mediated lysis, conjugate formation and adhesion molecules expression in non Hodgkin's lymphomas. Leukemia and Lymphoma 1997; 28: 133–143
   PubMed Web of Science ®Google Scholar
• Qian K, Vaux D. L., Weissman I. L. Expression of the integrin 4aL4β1 on melanoma cells can inhibit the invasive stage of metastasis formation. Cell 1994; 77: 335–347
   PubMed Web of Science ®Google Scholar
• Moller P., Hammerling G. J. The role of surface HLA-A,B,C molecules in tumour immunity. Cancer Surv 1992; 13: 101–27
   PubMedGoogle Scholar
• Shieh D.-C., Gammon M. C., Zweering H. J., Kao K. J. Functional significance of varied quantitative and qualitative expression of HLA-A2.1 antigens in determining the susceptibility of cells to cytotoxic T lymphocytes. Human Immunol 1996; 46: 18–26
   PubMed Web of Science ®Google Scholar
• Rivoltini L., Barracchini K. C., Viggiano V., Kawakami Y, Smith A., Mixon A., Restifo N. P., Topalian S. L., Simonis T. B., Rosenberg S. A., Marincola F. M. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res 1995; 55: 3149–3157
   PubMed Web of Science ®Google Scholar
• Torres M. J., Ruizcabello R., Skoudy A., Berrozpe G., Jimenez P., Serrano A., Real F. X., Garrido F. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Tissue Antigens 1996; 47: 372–381
   PubMed Web of Science ®Google Scholar
• Hiraki A., Kaneshige T., Kiura K., Ueoka H., Yamane H., Tanaka M., Harada M. Loss of HLA haplotype in lung cancer cell lines: implications for immunosur-veillance of altered HLA class I/II phenotypes in lung cancer. Clin Cancer Res 1999; 5: 933–936
   PubMed Web of Science ®Google Scholar
• Wang Z., Margulies L., Hicklin D. J., Ferrone S. Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class i antigen expression. Tissue Antigens 1996; 47: 382–390
   PubMed Web of Science ®Google Scholar
• Perez B., Benitez R., Fernandez M. A., Oliva M R., Soto J. L., Serrano S., Lopez Nevot M. A., Garrido F. A new beta2 microglobulin mutation found in a melanoma tumor cell line. Tissue Antigens 1999; 53: 569–572
   PubMed Web of Science ®Google Scholar
• Benitez R., Godelaine D., Lopez Nevot M. A., Brasseur F., Jimenez P., Marchand M., Oliva M R., Van Baren N., Cabrera T., Andry G., Landry C., Ruiz Cabeilo P., Boon T., Garrido R. Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 1998; 52: 520–529
   PubMed Web of Science ®Google Scholar
• Weiss S., Bogen B. B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells. Proc. Natl. Acad. Sci. USA 1989; 86: 282–286
   PubMed Web of Science ®Google Scholar
• Jacob M. C., Masson D., Plumas J., Chaperot L., Favre M., Gressin R., Bensa J. C. Analysis of HLA-I defects on the surface of malignant lymphoma B-cells (B-NHL) by CMF (Abstract). A.C. Pathol 1997; 14: 188
   Google Scholar
• Amiot L., Onno M., Lamy T., Dauriac C., Le Prise J.-Y., Fauchet R., Drenou B. Loss of HLA molecules in B lymphomas is associated with an aggressive clinical course. Br. J. Haematol 1998; 100: 655–663
   PubMed Web of Science ®Google Scholar
• Moller P., Herrmann B., Moldenhauer G., Momburg R. Defective expression of MHC class I antigens is frequent in B-cell lymphomas of high grade malignancy. Int. J. Cancer 1987; 40: 32–39
   PubMed Web of Science ®Google Scholar
• Plumas J., Chaperot L., Jacob M. C., Giroux C., Mollens J. P., Sotto J. J., Bensa J. C. Malignant B lymphocytes induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures. Eur. J. Immunol 1995; 25: 3332–3341
   PubMed Web of Science ®Google Scholar
• Garban E, Truman J. P., Lord J., Drenou B., Plumas J., Jacob M. C., Sotto J. J., Charron D., Mooney N. Signal transduction via human leucocyte antigen class II molecules distinguishes between cord blood, normal, and malignant adult B lymphocytes. Exp Hematol 1998; 26: 874–884
   PubMed Web of Science ®Google Scholar
• Pazmany L., Mandelboim O., Valesgomez M., Davis D. M., Reyburn H. T., Strominger J. L. Protection from natural killer cell-mediated lysis by HLA-G expression on target cells. Science 1996; 274: 792–795
   PubMed Web of Science ®Google Scholar
• Rajagopalan S., Long E. O. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med 1999; 189: 1093–1100
   PubMed Web of Science ®Google Scholar
• Le Gal F. A., Riteau B., Sedlik C., Khalil Daher I., Menier C., Dausset J., Guillet J. G., Carosella E. D., Freiss Rouas N. HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol 1999; 11: 1351–1356
   PubMed Web of Science ®Google Scholar
• Paul P., Rouas Preiss N., Khalil Daher I., Moreau P., Riteau B., Le Gal F. A., Avril M. R., Dausset J., Guillet J. G., Carosella E. D. HLA-G expression in melanoma: a way for tumor cells to escape from immuno-surveillance. Proc Natl Acad Sci U S A 1998; 95: 4510–4515
   PubMed Web of Science ®Google Scholar
• Paul P., Cabestre F. A., Le Gal F. A., Khalil Daher I., Le Danff C., Schmid M., Mercier S., Avril M. F., Dausset J., Guillet J. G., Carosella E. D. Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res 1999; 59: 1954–1960
   PubMed Web of Science ®Google Scholar
• Real L. M., Cabrera T., Collado A., Jimenez P., Garcia A., Ruiz Cabello F., Garrido F. Expression of HLA G in human tumors is not a frequent event. Int J Cancer 1999; 81: 512–518
   PubMed Web of Science ®Google Scholar
• Amiot L., Onno M., Renard D., Drenou B., Guillaudeux T, Le Bouteiller P., Fauchet R. HLA-G transcription studies during the different stages of normal and malignant hematopoiesis. Tissue Antigens 1996; 48: 609–614
   PubMedGoogle Scholar
• Van den Eynde B., Bruggen V. D. T cell defined tumor antigens. Curr. Opin. Immunol 1997; 9: 684–693
   PubMed Web of Science ®Google Scholar
• Stevenson F. K., Zhu D., King C. A., Ashworth L. J., Kumar S., Hawkins R. E. Idiotypic DNA vaccines against B-cell lymphoma. Immunol Rev 1995; 145: 211–228
   PubMed Web of Science ®Google Scholar
• Terness P., Welschof M., Moldenhauer G., Jung M., Moroder L., Kirchhoff E, Kipriyanov S., Little M., Opelz G. Idiotypic vaccine for treatment of human B-cell lymphoma - Construction of IgG variable regions from single malignant B cells. Hum Immunol 1997; 56: 17–27
   PubMed Web of Science ®Google Scholar
• Chambost H., Van Baren N., Brasseur F., Godelaine D., Theate I., Spagnoli G. C., Xerri L., Plumas J., Michel G., Coulie P., Olive D. (Submitted) Expression of gene MAGE-A4 In Reed Sternberg cells
   Google Scholar
• Vonderheide R. H., Hahn W. C., Schultze J. L., Nadler L. M. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999; 10: 673–679
   PubMed Web of Science ®Google Scholar
• Whang-Peng J., Knutsen T., Jaffe E. S., Steinberg S. M., Raffeld M, Zhao W. P., Duffey P., Condron K., Yano T., Longo D. L. Sequential analysis of 43 patients with non-hodgkin's lymphoma: clinical correlations with cytogenetic, histologic, immunophenotyping, and molecular studies. Blood 1995; 85: 203–216
   PubMed Web of Science ®Google Scholar
• Mannering S. I., McKenzie J. L., Feamley D. B., Hart D. N.J. HLA-DR1-restricted bcr-ab1 (b3a2)-specific CD4(+) T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates. Blood 1997; 90: 290–297
   PubMed Web of Science ®Google Scholar
• Nieda M, Nicol A., Kikuchi A., Kashiwase K., Taylor K., Suzuki K., Tadokoro K., Juji T. Dendritic cells stimulate the expansion of bcr-ab1 specific CD8(+) T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood 1998; 91: 977–983
   PubMed Web of Science ®Google Scholar
• Freeman G. J., Freedman A. S., Segil J. M., Lee G., Whitman J. F., Nadler L. M. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J. Immunol 1989; 143: 2714–2722
   PubMed Web of Science ®Google Scholar
• Freeman G. J., Gribben J. G., Boussiotis V. A., Ng J. W., Restivo V. A., Lombard L. A., Gray G. S., Nadler L. M. Cloning of B7–2 - a CTLA-4 counter-receptor that costimulates human T-Cell proliferation. Science 1993; 262: 909–911
   PubMed Web of Science ®Google Scholar
• June C., Ledbetter J., Linsley P., Thompson C. Role of the CD28 receptor in T cell activation. J. Immunol 1990; 11: 211–216
   Google Scholar
• Norton S., Zuckerman L., Urdahl K., Shefner R., Miller J., Jenkins M. The CD28 ligand, B7, enhances IL-2 production by providing a costimulatory signal to T cells. J. Immunol 1992; 149: 1556–1561
   PubMed Web of Science ®Google Scholar
• Noel P. J., Boise L. H., Green J. M., Thompson C. B. CD28 costimulation prevents cell death during primary T cell activation. J Immunol 1996; 157: 636–642
   PubMed Web of Science ®Google Scholar
• Radvanyi L. G., Shi Y. F., Vaziri H., Sharma A., Dhala R., Mills G. B., Miller R. G. CD28 costimulation inhibits TCR-induced apoptosis during a primary t cell response. J Immunol 1996; 156: 1788–1798
   PubMed Web of Science ®Google Scholar
• Walunas T. L., Bakker C. Y., Bluestone J. A. CTLA-4 ligation blocks CD28-dependem T cell activation. J Exp Med 1996; 183: 2541–2550
   PubMed Web of Science ®Google Scholar
• Walunas T. L., Lenschow D. J., Bakker C. Y., Linsley P. S., Freeman G. J., Green J. M., Thompson C. B., Blue-Stone J. A. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1: 405–413
   PubMed Web of Science ®Google Scholar
• Lee K.-M., Chuang E., Griffin M., Khattri R., Hong D. K., Zhang W., Straus D., Samelson L. E., Thompson B. C., Bluestone J. A. Molecular bases of T cell inactivation by CTLA-4. Science 1998; 282: 2263–2266
   PubMed Web of Science ®Google Scholar
• Fraser J. H., Rincon M., McCoy K. D., Le Gros G. CTLA4 ligation attenuates AP-1, NFAT and NF-kappaB activity in activated T cells. Eur J Immunol 1999; 29: 838–844
   PubMed Web of Science ®Google Scholar
• Koulova L., Clark E. A., Shu G., Dupont B. The CD28 ligand B7/BB1 provides costimularory signal for alloactivation of CD4+ T cells. J. Exp. Med 1991; 173: 759–762
   PubMed Web of Science ®Google Scholar
• Azuma M., Cayabyab M. N., Buck D., Phillips J. H., Lanier L. L. CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. J. Exp. Med 1992; 175: 353–360
   PubMed Web of Science ®Google Scholar
• Schultze J. L., Cardoso A. A., Freeman G. J., Seamon M. J., Daley J., Pinkus G. S., Gribben J. G., Nadler L. M. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc. Natl. Acad. Sci. USA 1995; 92: 8200–8204
   PubMed Web of Science ®Google Scholar
• Chaperot L., Plumas J., Jacob M.-C., Bost F, Molens J.-P., Sotto J.-J., Bensa J.-C. Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas. Exp. Hemalol 1999; 27: 479–488
   PubMed Web of Science ®Google Scholar
• Vyth Dreese F. A., Boot H., Dellemijn T. A., Majoor D. M., Oomen L. C., Laman J. D., Van Meurs M., De Weger R. A., De Jong D. Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma. Immunology 1998; 94: 580–586
   PubMed Web of Science ®Google Scholar
• Vyth-Dreese F. A., Dellemijn T. A.M., Majoor D., De Jong D. Localization in situ of the co-stimulatory molecules B7.1, B7.2, CD40 and their ligands in normal lymphoid tissue. Eur. J. Immunol 1995; 25: 3023–3029
   PubMed Web of Science ®Google Scholar
• Yellin M. J., Sinning J., Covey L. R., Sherman W., Lee J. J., Glickman-Nir E., Sippel K. C., Rogers J., Cleary A. M., Parker M., Chess L., Lederman S. T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. J Immunol 1994; 153: 666–674
   PubMed Web of Science ®Google Scholar
• Ranheim E. A., Kipps T. J. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J. Exp. Med 1993; 177: 925–935
   PubMed Web of Science ®Google Scholar
• Watts T., Alaverdi N., Wade W., Linsley P. Induction of costimulatory molecule B7 in M12 B lymphomas by cAMP or MHC restricted T cell interaction. J. Immunol 1993; 150: 2192–2202
   PubMed Web of Science ®Google Scholar
• Nabavi N., Freeman G., Gault A., Godfrey D., Nadler M., Glimcher L. Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature 1992; 360: 266–268
   PubMed Web of Science ®Google Scholar
• Vallé A., Aubry J.-P., Durand I., Banchereau J. IL-4 and IL-2 up-regulate the expression of antigen B7, the B cell counterstructure to T cell CD28: an amplification mechanism for T-B cell interactions. Int. Immunol 1991; 3: 229–235
   PubMed Web of Science ®Google Scholar
• Stack R. M., Lenschow D. J., Gray G. S., Bluestone J. A., Fitch F. W. IL-4 treatment of small splenic B cells induces costimulatory molecules B7–1 and B7–2. J Immunol 1994; 152: 5723–5733
   PubMed Web of Science ®Google Scholar
• Suda T., Takahashi T., Golstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the Tumor Necrosis Factor family. Cell 1993; 75: 1169–1178
   PubMed Web of Science ®Google Scholar
• Yonehara S., Ishii A., Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med 1989; 169: 1747–1756
   PubMed Web of Science ®Google Scholar
• Trauth B. C., Klas C., Peters A. M.J., Matzku S., Mbller P., Falk W., Debatin K. M., Krammer P. H. Monoclonal antibody mediated tumor regression by induction of apoptosis. Science 1989; 245: 301–305
   PubMed Web of Science ®Google Scholar
• Lowin B., Hahne M., Mattmann C., Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994; 370: 650–652
   PubMed Web of Science ®Google Scholar
• Kagi D., Vignaux E, Ledermann B., Burki K., Depraetere V, Nagata S., Hengartner H., Golstein P. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528–530
   PubMed Web of Science ®Google Scholar
• Rathmell J. C., Townsend S. E., Xu J. C., Flavell R. A., Goodnow C. C. Expansion or elimination of B cells in vivo: dual roles for CD40 and Fas (CD95) ligands modulated by the B cell antigen receptor. Cell 1996; 87: 319–329
   PubMed Web of Science ®Google Scholar
• Garrone P., Neidhardt E. M., Garcia E., Galibert L., Van Kooten C. J.B. Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J. Exp. Med 1995; 182: 1265–1273
   PubMed Web of Science ®Google Scholar
• Schattner E. J., Elkon K. B., Yoo D. H., Tumang J., Krammer P. H., Crow M. K., Friedman S. M. CD40 ligation induces apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the apo-1/Fas pathway. J Exp Med 1995; 182: 1557–1565
   PubMed Web of Science ®Google Scholar
• Plumas J., Jacob M. C., Chaperot L., Molens J. P., Sotto J. J., Bensa J. C. Tumor B cells from non-Hodg-kin's lymphoma are resistant to CD95 (Fas/Apo-l)-mediated apoptosis. Blood 1998; 91: 2875–2885
   PubMed Web of Science ®Google Scholar
• Möller P., Henne C., Leithauser F., Eichelmann A., Schmidt A., Brilderlein S., Dhein J., Krammer P. Coregulation of the APO-1 antigen with intercellular adhesion molecule-1 (CD54) on tonsillar B cells and coordinate expression in follicular center B cells and in follicle center and mediastinal B-cell lymphomas. Blood 1993; 81: 2067–2075
   PubMed Web of Science ®Google Scholar
• Lagresle C., Mondiere P., Bella C., Krammer P. H., Defrance T. Concurrent engagement of CD40 and the antigen receptor protects naive and memory human B cells from APO-1/Fas mediated apoptosis. J. Exp. Med 1996; 183: 1377–1388
   PubMed Web of Science ®Google Scholar
• Kondo E., Yoshino T, Yamadori I., Matsuo Y, Kawasaki N., Minowada J., Akagi T. Expression of bcl-2 protein and Fas antigen in non-Hodgkin's lymphomas. Am J Pathol 1994; 145: 330–337
   PubMed Web of Science ®Google Scholar
• Yang E., Korsmeyer S. J. Molecular thanatop-sis: a discourse on the BCL2 family and cell death. Blood 1996; 88: 386–401
   PubMed Web of Science ®Google Scholar
• Xerri L., Pare P., Brousset P., Schlaifer D., Hassoun J., Reed J. C., Krajewski S. Predominant expression of the long isoform of Bcl-X (Bcl-xL) in human lymphomas. Brit. J. Haematol 1996; 92: 900–906
   PubMed Web of Science ®Google Scholar
• Schneider T. J., Grillot D., Foote L. C., Nunez G. E., Rothstein T. L. Bcl-x protects primary B cells against Fas-mediated apoptosis. J Immunol 1997; 159: 4834–4839
   PubMed Web of Science ®Google Scholar
• Xerri L., Devilard E., Bouabdallah R., Hassoun J., Chaperot L., Birg F., Plumas J. Quantitative analysis detects ubiquitous expression of apoptotic regulators in B cell non-Hodgkin's lymphomas. Leukemia 1999; 13: 1548–1553
   PubMed Web of Science ®Google Scholar
• Okura T., Gong L., Kamitani T., Wada T, Okura I., Wei C.-E., Chang H.-M., Yeh E. T.H. Protection against Fas/APO-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin. J. Immunol 1996; 157: 4277–4281
   PubMed Web of Science ®Google Scholar
• Kataoka T, Schroter M., Hahne M., Schneider P., Irmler M., Thome M., Froelich C. J., Tschopp J. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J Immunol 1998; 161: 3936–3942
   PubMed Web of Science ®Google Scholar
• Schneider T. J., Fischer G. M., Donohoe T. J., Colarusso T. P., Rothstein T. L. A novel gene coding for a Fas inhibitory molecule (FAIM) isolated from inducibly Fas-resistant B lymphocytes. J. Immunol. 1999; 189: 949–955
   Google Scholar
• Kudoh S., Wang Q., Hidalgo O. F., Rayman P., Tubbs R. R., Edinger M. G., Kolenko V., Panuto J., Bukowski R., Finke J. H. Responses to T cell receptor CD3 and interleukin-2 receptor stimulation are altered in T cells from B cell non hodgkin's lymphomas. Cancer Immunol Immunother 1995; 41: 175–184
   PubMed Web of Science ®Google Scholar
• Wang Q., Stanley J., Kudoh S., Myles J., Kolenko V., Yi T. L., Tubbs R., Bukowski R., Finke J. T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell recep-tor/CD3-associated kinases are present. J Immunol 1995; 155: 1382–1392
   PubMed Web of Science ®Google Scholar
• Schwartzentruber D. J., Steler-Stevenson M., Rosenberg S. A., Topalian S. L. Tumor-infiltrating lymphocytes from select B-cell lymphomas secrete granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-a in response to autologous tumor stimulation. Blood 1993; 82: 1204–1211
   PubMed Web of Science ®Google Scholar
• Trinchieri G., Scott P. The role of interleukin 12 in the immune response, disease and therapy. Immunol Today 1994; 15: 460–463
   PubMedGoogle Scholar
• Zeh H. J., Hurd S., Storkus W. J., Lotze M. T. Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors - implications for the immunotherapy of cancer. J Immunother 1993; 14: 155–161
   PubMed Web of Science ®Google Scholar
• Durum S. K., Schmidt J. A., Oppenheim J. J. Interleukin 1: an immunological perspective. Ann. Rev. Immunol 1985; 3: 263–287
   PubMed Web of Science ®Google Scholar
• Chaperot L., Delfeau-Larue M.-H., Jacob M.-C., Molens J. P., Roussel B., Agrawal S., Farcet J.-P., Gressin R., Sotto J.-J., Bensa J.-C., Plumas J. Differentiation of antitumor-specific cytotoxic T lymphocytes from autologous tumor infiltrating lymphocytes in non-Hodgkin's lymphomas. Exp. Hematol. 1999; 27: 1185–1193
   PubMed Web of Science ®Google Scholar
• Hirohata S. Human Thl responses driven by IL-12 are associated with enhanced expression of CD40 ligand. Clin Exp Immunol 1999; 115: 78–85
   PubMed Web of Science ®Google Scholar
• Peng X., Remade J. E., Kasran A., Huylebroeck D., Ceuppens J. L. IL-12 up-regulates CD40 Ligand (CD 154) expression on human T cells. J. Immunol 1998; 160: 1166–1172
   PubMed Web of Science ®Google Scholar
• Schultze J. L., Seamon M. J., Michalak S., Gribben J. G., Nadler L. M. Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood 1997; 89: 3806–3816
   PubMed Web of Science ®Google Scholar
• Rathmell J. C., Cooke M. P., Ho W. Y., Grein J., Townsend S. E., Davis M. M., Goodnow C. C. CD95 (fas) dependent elimination of self reactive B cells upon interaction with CD4(+) T cells. Nature 1995; 376: 181–184
   PubMed Web of Science ®Google Scholar
• Voorzanger N., Touitou R., Garcia E., Delecluse H. J., Rousset F., Joab I., Favrot M. C., Blay J. Y. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 1996; 56: 5499–5505
   PubMed Web of Science ®Google Scholar
• Moore K. W., O'Garra A., De Waal Malefyt R., Vieira P., Mosmann T. R. Interleukin-10. Annu Rev Immunol 1993; 11: 165–190
   PubMed Web of Science ®Google Scholar
• Taga K., Mostowski H., Tosato G. Human interleukin-10 can directly inhibit T-cell growth. Blood 1993; 81: 2964–2971
   PubMed Web of Science ®Google Scholar
• Steinbrink K., Jonuleit H., Muller G., Schuler G., Knop J., Enk A. H. Interleukin-10-treated human dendritic cells induce a melanoma-antigen- specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood 1999; 93: 1634–1642
   PubMed Web of Science ®Google Scholar
• Buelens C., Willems E, Delvaux A., Pierard G., Delville J. P., Velu T., Goldman M. Interleukin-10 differentially regulates B7–1 (CD80) and B7–2 (CD86) expression on human peripheral blood dendritic cells. Eur J Immunol 1995; 25: 2668–2672
   PubMed Web of Science ®Google Scholar
• Bonnefoix T., Claret E., Piccini M. P., Jacob M. C., Zheng X., Sotto J. J. Detection, isolation and functional studies of CD25+ T cells in lymph nodes involved by B-cell non-Hodgkin's lymphomas. Scand. J. Immunol 1991; 34: 91–100
   PubMed Web of Science ®Google Scholar
• Diaz J. I., Edinger M. G., Stoler M. H., Tubbs R. R. Activated T-cell subsets in begnin lymphoid hyperplasias and B-cells non-Hodgkin's lymphomas. Am. J. Pathol 1991; 139: 503–509
   PubMed Web of Science ®Google Scholar
• Jacob M. C., Fabre M., LeMarc'Hadour E, Sotto M. F., Bonnefoix T, Sotto J. J., Bensa J. C. CD45RA expression by CD4 T lymphocytes in tumors invaded by B-cell non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD). Am. J. Hematol 1992; 39: 45–51
   PubMed Web of Science ®Google Scholar
• Agrawal S., Marquet J., Delfau Larue M. H., Copie Bergman C., Jouault H., Reyes E, Bensussan A., Farcet J. P. CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalig-nant secondary lymphoid organs. J Clin Invest 1998; 102: 1715–1723
   PubMed Web of Science ®Google Scholar
• Jacob M. C., Piccini M. P., Bonnefoix T., Sotto M. F., Couderc P., Bensa J. C., Sotto J. J. T lymphocytes from invaded lymph nodes in patients with B-cell-derived non-Hodgkin's lymphoma: reactivity toward the malignant clone. Blood 1990; 75: 1154–1162
   PubMed Web of Science ®Google Scholar
• Shi I., Bonnefoix X, Heuzelevacon E, Jacob M. C., Ler-Oux D., Gressin R., Sotto M. F., Chaffanjon P., Bensa J. C., Sotto J. J. Autotumour reactive T-cell clones among tumour-infiltrating T lymphocytes in B-cell non-hodgkin's lymphomas. Br J Haematol 1995; 90: 837–843
   PubMed Web of Science ®Google Scholar
• Umetsu D. T., Esserman L., Donlon T. A., DeKruyff R. H., Levy R. Induction of proliferation of human follicular (B type) lymphoma cells by cognate interaction with CD4+ T cell clones. J. Immunol 1990; 144: 2550–2557
   PubMed Web of Science ®Google Scholar
• Martin I., Bonnefoix T., Roucard C., Perron P., Laj-Manovich A., Moine A., Leroux D., Sotto J. J., Garban F. Role of autologous CD4+ T cell clones in human B non-Hodgkin's lymphoma: aborted activation and Gl blockade induced by ceel-cell contact. Eur. J. Immunol 1999, in press
   Web of Science ®Google Scholar
• Rohrer J. W., Coggin J. H. CD8 T cell clones inhibit antitumor T cell function by secreting IL-10. J Immunol 1995; 155: 5719–5727
   PubMed Web of Science ®Google Scholar
• Schwaller J., Tobler A., Niklaus G., Hurwitz N., Hennig I., Fey M. F., Borisch B. Interleukin-12 expression in human lymphomas and nonneoplastic lymphoid disorders. Blood 1995; 85: 2182–2188
   PubMed Web of Science ®Google Scholar